CO2022018464A2 - Agonistas dobles de glp-1/gip de acción prolongada - Google Patents
Agonistas dobles de glp-1/gip de acción prolongadaInfo
- Publication number
- CO2022018464A2 CO2022018464A2 CONC2022/0018464A CO2022018464A CO2022018464A2 CO 2022018464 A2 CO2022018464 A2 CO 2022018464A2 CO 2022018464 A CO2022018464 A CO 2022018464A CO 2022018464 A2 CO2022018464 A2 CO 2022018464A2
- Authority
- CO
- Colombia
- Prior art keywords
- gip
- long
- acting glp
- double agonists
- obesity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/645—Secretins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202021026360 | 2020-06-22 | ||
| IN202121002838 | 2021-01-20 | ||
| PCT/IB2021/055457 WO2021260530A1 (en) | 2020-06-22 | 2021-06-21 | Long acting glp-1/gip dual agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022018464A2 true CO2022018464A2 (es) | 2023-03-17 |
Family
ID=76891103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0018464A CO2022018464A2 (es) | 2020-06-22 | 2022-12-20 | Agonistas dobles de glp-1/gip de acción prolongada |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20230241178A1 (https=) |
| EP (1) | EP4146248A1 (https=) |
| JP (1) | JP7849310B2 (https=) |
| KR (1) | KR20230023658A (https=) |
| CN (1) | CN115768460A (https=) |
| AU (1) | AU2021296376A1 (https=) |
| BR (1) | BR112022025615A2 (https=) |
| CA (1) | CA3183358A1 (https=) |
| CL (1) | CL2022003654A1 (https=) |
| CO (1) | CO2022018464A2 (https=) |
| EC (1) | ECSP22095556A (https=) |
| IL (1) | IL299195A (https=) |
| JO (1) | JOP20220344A1 (https=) |
| MX (1) | MX2022016032A (https=) |
| PE (1) | PE20230861A1 (https=) |
| PH (1) | PH12022553526A1 (https=) |
| TW (1) | TW202216746A (https=) |
| WO (1) | WO2021260530A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20231309A1 (es) * | 2020-10-17 | 2023-08-24 | Sun Pharmaceutical Ind Ltd | Agonistas duales glp-1/gip |
| CA3204051A1 (en) | 2021-01-20 | 2022-07-28 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| US12281149B2 (en) | 2021-05-13 | 2025-04-22 | Carmot Therapeutics, Inc. | Modulators of G-protein coupled receptors |
| JP7642830B2 (ja) | 2021-09-15 | 2025-03-10 | バイキング・セラピューティクス・インコーポレイテッド | 代謝及び肝臓障害の処置のための組成物及び方法 |
| WO2024098718A1 (zh) * | 2022-11-07 | 2024-05-16 | 内蒙古博睿精创科技有限公司 | 一种新型长效多肽化合物、组合物及其应用 |
| CN120865433A (zh) * | 2022-12-21 | 2025-10-31 | 勃林格殷格翰国际有限公司 | Glp1/gip/npy2受体的三重激动剂 |
| WO2024165571A2 (en) | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| KR20260022948A (ko) | 2023-06-09 | 2026-02-20 | 썬 파마슈티컬 인더스트리스 리미티드 | Glp-1/gip 이중 수용체 작용제, glp-1/gcg 이중 수용체 작용제, 및 glp-1/gip/gcg 삼중 수용체 작용제 |
| WO2025125576A2 (en) | 2023-12-15 | 2025-06-19 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025133348A1 (en) | 2023-12-22 | 2025-06-26 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| EP4686757A1 (en) | 2024-07-31 | 2026-02-04 | e-therapeutics PLC | Inhibitors of expression and/or function |
| WO2025163615A1 (en) | 2024-01-31 | 2025-08-07 | Sun Pharmaceutical Industries Ltd. | High level production of glp1 analogues |
| WO2025196502A1 (en) | 2024-03-20 | 2025-09-25 | North Carolina Agricultural & Technical State University | Choline kinase inhibitors as a therapeutic treatment for obesity |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120123443A (ko) * | 2010-01-27 | 2012-11-08 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트 |
| IN2014MN02304A (https=) * | 2012-05-03 | 2015-08-07 | Zealand Pharma As | |
| WO2015067715A2 (en) | 2013-11-06 | 2015-05-14 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| TWI582109B (zh) * | 2015-01-09 | 2017-05-11 | 美國禮來大藥廠 | Ｇｉｐ及ｇｌｐ－１共促效劑化合物 |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| MX2020010505A (es) * | 2018-04-05 | 2021-01-15 | Sun Pharmaceutical Ind Ltd | Analogos novedosos de glp-1. |
| CN119499352A (zh) | 2018-07-23 | 2025-02-25 | 伊莱利利公司 | 使用gip/glp1共激动剂用于糖尿病的方法 |
| KR20240051304A (ko) * | 2018-07-23 | 2024-04-19 | 일라이 릴리 앤드 캄파니 | Gip/glp1 공효능제 화합물 |
-
2021
- 2021-06-18 TW TW110122388A patent/TW202216746A/zh unknown
- 2021-06-21 IL IL299195A patent/IL299195A/en unknown
- 2021-06-21 MX MX2022016032A patent/MX2022016032A/es unknown
- 2021-06-21 EP EP21740614.9A patent/EP4146248A1/en active Pending
- 2021-06-21 CA CA3183358A patent/CA3183358A1/en active Pending
- 2021-06-21 PH PH1/2022/553526A patent/PH12022553526A1/en unknown
- 2021-06-21 BR BR112022025615A patent/BR112022025615A2/pt unknown
- 2021-06-21 WO PCT/IB2021/055457 patent/WO2021260530A1/en not_active Ceased
- 2021-06-21 US US18/002,478 patent/US20230241178A1/en active Pending
- 2021-06-21 CN CN202180042855.9A patent/CN115768460A/zh active Pending
- 2021-06-21 AU AU2021296376A patent/AU2021296376A1/en active Pending
- 2021-06-21 JP JP2022578936A patent/JP7849310B2/ja active Active
- 2021-06-21 KR KR1020227043963A patent/KR20230023658A/ko active Pending
- 2021-06-21 PE PE2022002928A patent/PE20230861A1/es unknown
-
2022
- 2022-12-19 EC ECSENADI202295556A patent/ECSP22095556A/es unknown
- 2022-12-19 CL CL2022003654A patent/CL2022003654A1/es unknown
- 2022-12-20 JO JOJO/P/2022/0344A patent/JOP20220344A1/ar unknown
- 2022-12-20 CO CONC2022/0018464A patent/CO2022018464A2/es unknown
-
2024
- 2024-08-22 US US18/812,726 patent/US20240424063A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4146248A1 (en) | 2023-03-15 |
| MX2022016032A (es) | 2023-04-19 |
| US20230241178A1 (en) | 2023-08-03 |
| JP7849310B2 (ja) | 2026-04-21 |
| AU2021296376A1 (en) | 2022-12-08 |
| US20240424063A1 (en) | 2024-12-26 |
| PH12022553526A1 (en) | 2024-01-22 |
| CA3183358A1 (en) | 2021-12-30 |
| WO2021260530A1 (en) | 2021-12-30 |
| CN115768460A (zh) | 2023-03-07 |
| KR20230023658A (ko) | 2023-02-17 |
| JP2023530515A (ja) | 2023-07-18 |
| TW202216746A (zh) | 2022-05-01 |
| BR112022025615A2 (pt) | 2023-01-17 |
| JOP20220344A1 (ar) | 2022-12-20 |
| AU2021296376A8 (en) | 2022-12-22 |
| CL2022003654A1 (es) | 2023-08-04 |
| IL299195A (en) | 2023-02-01 |
| PE20230861A1 (es) | 2023-05-30 |
| ECSP22095556A (es) | 2023-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022018464A2 (es) | Agonistas dobles de glp-1/gip de acción prolongada | |
| CO2023001960A2 (es) | Agonistas duales glp-1/gip | |
| ECSP17043648A (es) | Compuestos co-agonistas de gip y glp-1 | |
| MY197569A (en) | Gip/glp1 co-agonist compounds | |
| CO2025001430A2 (es) | Agonista dual de glp-1/gip, método de preparación y uso del mismo | |
| BR112023024968A2 (pt) | Tratamento da obesidade e distúrbios relacionados à obesidade | |
| AR121093A1 (es) | Compuestos coagonistas de gip / glp1 | |
| CL2008003243A1 (es) | Compuesto que exhibe actividad antagonista del glucagon y actividad agonista del peptido-1 tipo glucagon (glp); composicion farmaceutica y kit que lo comprende; y su uso para tratar hiperglucemia. | |
| MX2021005725A (es) | Tratamiento de la obesidad y sus complicaciones. | |
| MX2026000195A (es) | Triagonista de los receptores glp-1, gip y gcg y su uso | |
| ECSP23019850A (es) | Agonistas duales glp-1/gip | |
| MX2021012177A (es) | Usos terapeuticos de dulaglutida. | |
| MX2024007449A (es) | Agonistas triples peptidicos del gip, glp-1 y glp-2. |